Jaehong Kim, Ph.D.

Jaehong Kim, Ph.D. is a health economist with research experience applying microeconomics theory and statistical methods to explore a wide range of topics in pharmaceutical and health economics.

During his Ph.D. studies, Dr. Kim examined the interplay between medical innovation and healthcare markets from an industrial organization perspective using drug pipeline data and administrative claims data. Some examples of his work include analysis of the role that the oligopolistic structure of the pharmaceutical market plays in firms’ R&D decisions and market efficiency of R&D investment. In other studies, he relied on various quasi-experimental methods to examine how the demand for health insurance responds to arrival of breakthrough healthcare technology, and how a pharmaceutical or biotechnology company adjusts its R&D portfolio in response to the upcoming patent expiration of its blockbuster drugs.

Dr. Kim has considerable experience of assessing the effectiveness and the economic value of new medical technology in a real-world setting. In collaboration with researchers from different disciplines such as medical and pharmaceutical sciences, he examined protective effect of verapamil on type 1 diabetes progression and evaluated the cost-effectiveness of regorafenib for advanced hepatocellular carcinoma patients. Also, in his study of health inequalities and healthcare access, Dr. Kim and his colleagues examined whether poor access to primary care physicians in rural areas causes urban-rural disparities in the diagnosis of Alzheimer’s Disease among the older population.

Dr. Kim received a doctorate degree in Health Economics from the University of Southern California and Master’s and Bachelor’s degrees in Economics from Korea University, Seoul, Republic of Korea.